NCT06966050

Brief Summary

To collect data from participants with IBC who may have had MRD testing and may have surgery in the future.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
71mo left

Started May 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress18%
May 2025May 2032

First Submitted

Initial submission to the registry

April 25, 2025

Completed
10 days until next milestone

Study Start

First participant enrolled

May 5, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 11, 2025

Completed
5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2030

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2032

Last Updated

May 20, 2026

Status Verified

May 1, 2026

Enrollment Period

5.1 years

First QC Date

April 25, 2025

Last Update Submit

May 18, 2026

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

  • European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire

    European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Score scale: (1-30 questions to assess the impact of participants quality of life)

    Through study completion; an average of 1 year

Study Arms (1)

Group 1

Participants will fill out a quality-of-life questionnaire and complete a MRD test.

Behavioral: Quality-of-life Questionnaire

Interventions

Quality-of-life QuestionnaireBEHAVIORAL

Participants will be asked to fill out a quality-of-life questionnaire, which will take about 10-15 minutes to complete.

Group 1

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

MD Anderson Cancer Center

You may qualify if:

  • Female or males ≥18 years of age with the ability to understand and sign a written
  • Participants who have a clinical diagnosis of stage III or IV inflammatory breast cancer (IBC).
  • Participants who are planning to have or already completed a minimum of one blood draw for Signatera testing, for which the result and clinical data can be deposited into the study database.
  • Participants must be within eight months of diagnosis and have not undergone breast surgery for this diagnosis of breast cancer.
  • Participants must be English-speaking.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MD Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Sadia Saleem, MD

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sadia Saleem, MD

CONTACT

281-566-1900ssaleem@mdanderson.org

Angela Alexander

CONTACT

713-792-9137aalexand@mdanderson.org

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 25, 2025

First Posted

May 11, 2025

Study Start

May 5, 2025

Primary Completion (Estimated)

May 31, 2030

Study Completion (Estimated)

May 31, 2032

Last Updated

May 20, 2026

Record last verified: 2026-05

Locations

US(1)